Avacta and Glythera collaborate to develop novel, potentially highly potent, drug class
![](/46/pdcnewsitem/04/17/33/avacta.png)
The collaboration will evaluate the use of Avacta’s Affimer technology in combination with Glythera’s PermaLink conjugation chemistry.
Avacta Group the developer of Affimer biotherapeutics and research reagents, and Glythera, the developer of advanced, stable conjugation chemistries and novel, ultra-potent toxin payloads, have established a collaboration to evaluate the use of Glythera’s PermaLink conjugation chemistry in combination with Avacta’s Affimer technology with the aim of developing a new class of highly targeted bio-therapeutics as a superior alternative to the established class of antibody drug conjugates (ADCs).
The combined potential benefits of the Affimer and PermaLink technologies have the potential to create an analogous leading protein drug conjugate platform with a number of benefits over current ADC offerings. Use of Avacta’s Affimer technology provides the ability to closely control the position and number of toxins in the payload; has the benefit of much shorter development times (has the flexibility to “design-in” the required pharmacokinetics (the time the drug spends in the blood stream), and is much easier, more consistent and has lower cost production. The small size of the Affimer molecule is likely to also improve tumour penetration compared with antibodies which are ten times larger in size.
Another major issue facing ADCs is the limited stability of chemical linkages currently used to attach the toxin to the antibody resulting in the toxin coming off the antibody and causing “off-target” and often severe, side effects. Glythera’s PermaLink chemical linkers provide much more stable attachment of the toxin/chemotherapy and can potentially reduce such off-target toxicity effects.
Under the terms of the agreement, the companies will develop materials and methods to be used in the generation of Affimer-drug conjugates. The proof of concept study aims to demonstrate the key technical and commercial benefits of the combination over traditional antibody and linker approaches. The two companies will partner to offer Affimer-drug conjugate development services, and licensing of the combined platform, to pharmaceutical developers.
Dr Alastair Smith, CEO, Avacta, commented: “At the half year we set out a detailed commercial strategy for Affimer reagents and therapeutics. We highlighted the importance of commercial partnerships in order to make rapid progress in the areas of strategic focus. In that context we recently announced a collaboration with Mologic to develop Affimer based lateral flow devices which would open up the rapid diagnostics market opportunity and today we are very pleased to report the establishment of this collaboration with Glythera in the area of ADCs, another important application area for Affimer technology.
Avacta’s Affimer technology has significant benefits for drug conjugate development, and the combination of the two companies’ technologies has the potential to deliver a best-in-class solution for those wishing to access such a platform. We are therefore confident that this partnership with Glythera will further demonstrate the utility of the Affimer platform as a powerful approach to generating a broad range of biotherapeutics, creating opportunities for third party licensing of the platform with the potential to generate long-term value for both companies.
We continue to make good progress across all aspects of the strategy that we set out and I look forward to further updating the market in due course.”
Dr Dave Simpson, CEO Officer, Glythera, said: “Combining Glythera’s PermaLink conjugation chemistry with Avacta’s Affimer technology will demonstrate the benefits of PermaLink across a new targeting molecule class, opening additional avenues for bringing novel therapeutic assets to market. This is an exciting step forward in bio-therapeutic development, and could lead to improved patient outcomes.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance